Ifosfamide
- Generic Name
- Ifosfamide
- Brand Names
- Ifex
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 3778-73-2
- Unique Ingredient Identifier
- UM20QQM95Y
- Background
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
- Indication
Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...
- Associated Conditions
- Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
- Associated Therapies
- -
Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin
- Conditions
- First Posted Date
- 2003-09-18
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT00002559
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
- Conditions
- First Posted Date
- 2003-07-24
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- The Christie NHS Foundation Trust
- Registration Number
- NCT00004887
- Locations
- 🇬🇧
Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom
Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor
- Conditions
- Interventions
- Biological: filgrastimDrug: amifostine trihydrateDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: ifosfamideDrug: topotecan hydrochlorideDrug: vincristine sulfateProcedure: conventional surgeryRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET electron therapyRadiation: low-LET photon therapy
- First Posted Date
- 2003-06-18
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 130
- Registration Number
- NCT00002643
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸Long Beach Memorial Medical Center, Long Beach, California, United States
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇪🇬National Cancer Institute of Egypt, Cairo, Egypt
🇮🇳Kidwai Memorial Institute of Oncology, Bangalore, India
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 38
- Registration Number
- NCT00061893
- Locations
- 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, Huntington, West Virginia, United States
Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
- Conditions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2014-10-27
- Target Recruit Count
- 455
- Registration Number
- NCT00061984
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇨🇭Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇨🇦Doctor H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
- First Posted Date
- 2003-05-21
- Last Posted Date
- 2013-08-21
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 83
- Registration Number
- NCT00005977
- Locations
- 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸Texas Oncology P.A., Dallas, Texas, United States
Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-05-14
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004916
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-04-18
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 16
- Registration Number
- NCT00003597
- Locations
- 🇺🇸
Long Beach Memorial Medical Center, Long Beach, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 400
- Registration Number
- NCT00002822
- Locations
- 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.